CorMedix Inc. - Common Stock (CRMD)

Discover how CORMEDIX INC (CRMD) aligns with Louis Navellier’s growth investing strategy, showcasing strong earnings momentum, rapid revenue growth, and high ROE for potential stock gains.

Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.

CorMedix Inc (CRMD) reported strong Q2 2025 earnings, beating revenue and EPS estimates, with shares rising in pre-market trading. The company also announced the acquisition of Melinta Therapeutics.

CorMedix boosts Q2 sales forecast as a major dialysis client accelerates DefenCath use, prompting positive analyst coverage and growth outlook.

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network.

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

DefenCath, CorMedix’s lead product, was launched in hospitals in April 2024 and in outpatient settings in July 2024 following FDA approval.

CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.

CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter.

The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data.

The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78 million.

CRMD earnings call for the period ending December 31, 2024.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.